Search results for " type II"

showing 10 items of 542 documents

Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II

2010

Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is an X-linked, recessive, lysosomal storage disorder caused by deficiency of iduronate-2-sulfatase. It has multisystemic involvement, with manifestations in the brain, upper respiratory tract, heart, abdomen, joints and bones. Bone involvement leads to decreased growth velocity and short stature in nearly all patients. A therapeutic option for patients with MPS II is enzyme replacement therapy (ERT) with idursulfase (Elaprase®). We compared annual growth rates before and during ERT in 18 patients from Mainz, Germany, and Manchester, UK. Group 1 included nine patients who started ERT before 10 years of age; group 2 contained nine patie…

AdultMalemedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesAdolescentIdursulfaseIduronate SulfatasePlaceboShort staturePlacebosYoung AdultChild DevelopmentClinical Trials Phase II as TopicmedicineGeneticsHumansGenetics(clinical)Enzyme Replacement TherapyMucopolysaccharidosis type IIYoung adultGrowth ChartsChildGenetics (clinical)Mucopolysaccharidosis IIbusiness.industrynutritional and metabolic diseasesHunter syndromeEnzyme replacement therapymedicine.diseaseBody HeightSurgerymedicine.anatomical_structureClinical Trials Phase III as TopicAbdomenOriginal Articlemedicine.symptombusinessmedicine.drugJournal of Inherited Metabolic Disease
researchProduct

Nitric oxide production and endothelium-dependent vasorelaxation ameliorated by N1-methylnicotinamide in human blood vessels.

2012

N 1 -methylnicotinamide (MNA + ) has until recently been thought to be a biologically inactive product of nicotinamide metabolism in the pyridine nucleotides pathway. However, the latest observations imply that MNA + may exert antithrombotic and anti-inflammatory effects through direct action on the endothelium. We examined both in vivo and in vitro whether the compound might induce vasorelaxation in human blood vessels through the improvement of nitric oxide (NO) bioavailability and a reduction of oxidative stress mediated by endothelial NO synthase (eNOS) function. MNA + treatment (100 mg/m 2 orally) in healthy normocholesterolemic and hypercholesterolemic subjects increased the l-argini…

AdultNiacinamidemedicine.medical_specialtyEndotheliumBrachial ArteryNitric Oxide Synthase Type IIIHypercholesterolemiachemistry.chemical_elementCalciumIn Vitro Techniquesmedicine.disease_causeNitric OxideNitric oxidechemistry.chemical_compoundN^{1}-methylnicotinamideDouble-Blind MethodEnosnitric oxideInternal medicineInternal MedicinemedicineHumansflow-mediated dilationCalcimycinCells Culturedendothelial nitric oxide synthaseoxidized low-density lipoproteinbiologyDose-Response Relationship DrugChemistrySuperoxidebiology.organism_classificationendothelial cellsAcetylcholineOxygenVasodilationOxidative Stressmedicine.anatomical_structureEndocrinologysuperoxideEndothelium VascularAcetylcholineOxidative stressmedicine.drugLipoproteinHypertension (Dallas, Tex. : 1979)
researchProduct

Six novel mutations of the LDL receptor gene in FH kindred of Sicilian and Paraguayan descent

2006

Familial hypercholesterolemia (FH) is an autosomal dominant inherited disease caused by mutations in the gene coding for the low density lipoprotein receptor (LDL-R). It is characterized by a high concentration of low density lipoprotein (LDL), which frequently gives rise to premature coronary artery disease. We studied the probands of five FH Sicilian families with 'definite' FH and one proband of Paraguayan descent with homozygous FH who has been treated with an effective living-donor liver transplantation. In order to seek the molecular defect in these six families, we used direct sequencing to define the molecular defects of the LDL-R gene responsible for the disease. We described three…

AdultProbandhypercholesterolemia LDL receptor gene mutation analysis direct sequencing splicing living-donor transplantationSettore MED/09 - Medicina InternaDNA Mutational AnalysisDirect sequencingHypercholesterolemiaFamilial hypercholesterolemiaBiologyGene mutationSplicingmedicine.disease_causeFrameshift mutationHyperlipoproteinemia Type IIExonGeneticsmedicineHumansMissense mutationRNA MessengerChildSicilyCells CulturedLiving-donor transplantationLDL receptor geneGeneticsMutationIntronExonsGeneral MedicineMiddle Agedmedicine.diseaseLipidsMolecular biologyPedigreeDirect sequencing; Hypercholesterolemia; LDL receptor gene; Living-donor transplantation; Mutation analysis; SplicingMutation analysisReceptors LDLParaguayChild PreschoolMutationBiological Assay
researchProduct

Cell Death and Oxidative Damage in Inflammatory Myopathies

1998

There is evidence that muscle fibers in denervating disorders and muscular dystrophies undergo apoptosis. In 21 patients with autoimmune inflammatory myopathies, we found no features of muscle fiber apoptosis such as DNA fragmentation or expression of apoptosis-related proteins. However, muscle fibers in myositis displayed distinct up-regulation of inducible and neuronal nitric oxide synthase (NOS). While inducible NOS was distinctly up-regulated on the sarcolemma of all kinds of muscle fibers neuronal NOS displayed increased expression in the sarcoplasm of damaged as well as atrophic muscle fibers. There were no disease-specific patterns in the different myositis subtypes. Enhanced express…

AdultProgrammed cell deathNecrosisAdolescentImmunologySarcoplasmNitric Oxide Synthase Type IIApoptosisNitric Oxide Synthase Type IDermatomyositisMyositis Inclusion BodyPathology and Forensic MedicineMiceReference ValuesMuscle fiber necrosismedicineAnimalsHumansImmunology and AllergyChildMuscle SkeletalMyositisAgedSarcolemmaCell DeathbiologyInfantDNAMiddle Agedmedicine.diseasePolymyositisCell biologyNitric oxide synthaseOxidative StressApoptosisChild PreschoolImmunologybiology.proteinRabbitsNitric Oxide Synthasemedicine.symptomClinical Immunology and Immunopathology
researchProduct

NO Reduces PMN Adhesion to Human Vascular Endothelial Cells Due to Downregulation of ICAM-1 mRNA and Surface Expression

2000

Reperfusion damage is largely due to the adherence of polymorphonuclear leukocytes to the endothelium initiated by adhesion molecule upregulation. The reduced endothelial nitric oxide release during ischemia may be involved in the upregulation of intercellular adhesion molecule 1. In this study, we tested if nitric oxide donors suppress polymorphonuclear leukocyte adherence to activated endothelial cells by inhibition of the intercellular adhesion molecule 1 surface expression. Confluent human umbilical vein endothelial cells were stimulated with tumor necrosis factor alpha (300 U/mL) after preincubation with increasing concentrations of the nitric oxide donors CAS 1609 (0.005-5 mM/L) and 3…

AdultUmbilical VeinsEndotheliumNeutrophilsIntercellular Adhesion Molecule-1Cell Culture TechniquesDown-RegulationNitric Oxide Synthase Type IINitric OxideTransfectionUmbilical veinNitric oxidechemistry.chemical_compoundmedicineCell AdhesionHumansSaphenous VeinRNA MessengerICAM-1biologyTumor Necrosis Factor-alphaMembrane ProteinsHematologyIntercellular Adhesion Molecule-1Molecular biologyEndothelial stem cellNitric oxide synthasemedicine.anatomical_structurechemistryBiochemistryGene Expression Regulationbiology.proteinTumor necrosis factor alphaEndothelium VascularNitric Oxide Synthase
researchProduct

Development and Aging Are Oxygen-Dependent and Correlate with VEGF and NOS along Life Span

2012

During development and aging, vascular remodeling represents a critical adaptive response to modifications in oxygen supply to tissues. Hypoxia inducible factor (HIF) has a crucial role and is modulated by oxygen levels, with an age-dependent response in neonates, adult, and aged people. ROS are generated under hypoxic conditions and the accumulation of free radicals during life reduces the ability of tissues to their removal. In this immunohistochemical study we investigated the presence and localization of VEGF and iNOS in human carotid bodies (CB) sampled at autopsy from three children (mean age – 2 years), four adult young subjects (mean age – 44.3 years), and four old subjects (mean ag…

AdultVascular Endothelial Growth Factor AAgingmedicine.medical_specialtyNitric Oxide Synthase Type IIAutopsyBiologyHypoxemiaNitric oxideYoung Adultchemistry.chemical_compoundAnoxiaInternal medicinemedicineHumansYoung adultChildPreschoolAgedCarotid BodyAdult; Aged; Aging; Anoxia; Carotid Body; Cell Differentiation; Child Preschool; Humans; Nitric Oxide Synthase Type II; Oxygen; Vascular Endothelial Growth Factor A; Young AdultCell DifferentiationHypoxia (medical)Oxygenmedicine.anatomical_structureEndocrinologyHypoxia-inducible factorschemistryImmunohistochemistryCarotid bodymedicine.symptom
researchProduct

Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy.

2009

Background Hereditary angioedema caused by mutations in the factor XII gene is a recently described disease entity that occurs mainly in women. It differs from hereditary angioedema caused by C1 inhibitor deficiency. Objective To assess the clinical symptoms, factors triggering acute attacks, and treatments of this disease. Methods Thirty-five female patients with hereditary angioedema and the factor XII mutations p.Thr309Lys and p.Thr309Arg who came from 13 unrelated families were studied. The observation period was 8.4 years on average (range, 2-26 years). Results Patients had on average 12.7 ± 7.9 angioedema attacks per year. Recurrent facial swellings occurred in all patients; skin swel…

Adultmedicine.medical_specialtyAbdominal painAdolescentmedicine.medical_treatmentImmunologyMutation MissenseSeverity of Illness IndexC1-inhibitorYoung AdultRisk FactorsSurveys and QuestionnairesImmunology and AllergyMedicineHumansHereditary Angioedema Type IIIAge of OnsetChildProgesteroneDanazolPregnancyAngioedemabiologybusiness.industryDanazolAngioedemas HereditaryHormone replacement therapy (menopause)Middle Agedmedicine.diseaseDermatologySurgeryPedigreeTranexamic AcidHereditary angioedemaFactor XIIbiology.proteinFemalemedicine.symptombusinessmedicine.drugThe Journal of allergy and clinical immunology
researchProduct

A new PCSK9 gene promoter variant affects gene expression and causes autosomal dominant hypercholesterolemia.

2008

Autosomal dominant hypercholesterolemia (ADH) is a genetic disorder characterized by increased low-density lipoprotein (LDL)-cholesterol levels, leading to high risk of premature cardiovascular disease. More than 900 mutations in LDL receptor, six in APOB and 10 in PCSK9 have been identified as a cause of the disease in different populations. All known mutations in PCSK9 causing hypercholesterolemia produce an increase in the enzymatic activity of this protease. Up to now, there are data about the implication of PCSK9 in ADH in a low number of populations, not including a Spanish population.The objective of the study was to study the prevalence of PCSK9 mutations in ADH Spanish population.W…

Adultmedicine.medical_specialtyApolipoprotein BEndocrinology Diabetes and MetabolismClinical BiochemistryGene ExpressionTransfectionBiochemistryPolymorphism Single NucleotideHyperlipoproteinemia Type IIPCSK9 GeneMiceEndocrinologyGene FrequencyInternal medicinemedicineAnimalsHumansPromoter Regions GeneticAllele frequencyGeneCells CulturedGeneticsbiologyBase SequencePCSK9Biochemistry (medical)Serine EndopeptidasesGenetic disorderHyperlipoproteinemia Type IIaMiddle Agedmedicine.diseaseEndocrinologySpainCase-Control StudiesLDL receptorbiology.proteinNIH 3T3 Cellslipids (amino acids peptides and proteins)Mutant ProteinsProprotein ConvertasesProprotein Convertase 9The Journal of clinical endocrinology and metabolism
researchProduct

Expanding the clinical spectrum of late-onset Pompe disease: Dilated arteriopathy involving the thoracic aorta, a novel vascular phenotype uncovered

2011

Abstract Purpose Cerebro-vascular arteriopathy has been reported in late-onset Pompe disease (LOPD). Evidence of increased aortic stiffness in some patients and smooth muscle involvement in LOPD raises the possibility of aortic involvement. Our aim was to determine if aortic arteriopathy may be a complication of LOPD. Methods One patient with LOPD was diagnosed with aortic dilatation at Duke Metabolic clinic, 4 others were diagnosed at University of Mainz, Germany, where chest X-ray and echocardiography are routinely done for patients. Other causes of aortic vascular disease were assessed. Results We report evidence of dilated arteriopathy involving primarily the ascending thoracic aorta in…

Adultmedicine.medical_specialtyEndocrinology Diabetes and MetabolismAortic DiseasesAorta ThoracicDissection (medical)030204 cardiovascular system & hematologyBiochemistry03 medical and health sciences0302 clinical medicineEndocrinologyBicuspid aortic valveEctasiamedicine.arteryInternal medicineAscending aortaGeneticsmedicineHumansThoracic aortaMolecular BiologyAortaGlycogen Storage Disease Type IIbusiness.industryVascular diseaseMiddle Agedmedicine.disease3. Good healthPhenotypeChild Preschoolcardiovascular systemCardiologyFemaleRadiologyComplicationbusiness030217 neurology & neurosurgeryDilatation PathologicMolecular Genetics and Metabolism
researchProduct

Extracorporeal circuit heparinization in selective low density lipoprotein apheresis: changes in patient hemostasis and low molecular weight heparin …

1993

Treatment by low density lipoprotein (LDL) apheresis using dextran sulfate columns (DSC) leads to hemostasis alterations with prolonged activated partial thromboplastin time (APTT) of more than 120 seconds. In order to explain this hypocoagulability, we studied hemostasis parameters both in patients and in the extracorporeal circulation (ECC). Hemostasis changes are first related to unfractionated heparin (UFH)—needed to avoid circuit coagulation—which leads to high residual heparinemia in the patient (more than 3 times the recommended level for therapeutic use). Second, the hypocoagulability is induced by a coagulation factor decrease (primarily factors V, VIH, and X) mainly due to an adso…

Adultmedicine.medical_specialtyExtracorporeal Circulationmedicine.drug_classLow molecular weight heparinHyperlipoproteinemia Type IIInternal medicinemedicineHumansHemostasismedicine.diagnostic_testbusiness.industryExtracorporeal circulationAnticoagulantDextran SulfateNadroparinHematologyGeneral MedicineHeparinMiddle AgedBlood Coagulation FactorsSurgeryLipoproteins LDLApheresisLDL apheresisHemostasisCardiologyBlood Component RemovalbusinessPartial thromboplastin timemedicine.drugJournal of clinical apheresis
researchProduct